A study from the Department of Cancer Biology, Dana-Farber Cancer Institute; Department of Cell Biology, Harvard Medical School, USA shows that “Cyclin D1–Cdk4 controls glucose metabolism independently of cell cycle progression.”
This study was published in the June 26, 2014 Nature [I.F >35] by Prof. Puigserver and others from the Department of Cancer Biology, Dana-Farber Cancer Institute; Department of Cell Biology, Harvard Medical School, USA.
On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: Therapeutic insights into T2D: FBXO31 promotes gluconeogenesis and hyperglycemia via down regulation of Cyclin D1. This study suggests that FBXO31, by down regulating its target gene, it may promote gluconeogenesis and hyperglycemia. Together, this study suggests that pharmacological formulations encompassing “small molecule inhibitors of FBXO31“ may be used in the treatment of NIDDM.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Therapeutic insights into T2D: FBXO31 promotes gluconeogenesis and hyperglycemia via down regulation of Cyclin D1, Genome-2-Bio-Medicine Discovery center (GBMD), 24/08/2014, 6.29 am., http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
